Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cutaneous nocardiosis complicating management of Crohn's disease with infliximab and prednisone.

Literature DB >> 15505269

Cutaneous nocardiosis complicating management of Crohn's disease with infliximab and prednisone.

Sheldon M Singh¹, Neil V Rau, Lawrence B Cohen, Howard Harris.

Abstract

Infliximab is a chimeric anti-tumour necrosis factor-alpha antibody that is efficacious in treating Crohn's disease. However, its immunomodulatory properties increase susceptibility to opportunistic infections. We present a case of cutaneous Nocardia infection in a patient who was taking infliximab for Crohn's disease. The case illustrates the challenges in the diagnosis and management of this disease and serves as a reminder of the complications associated with the use of immunomodulatory agents.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2004 PMID： 15505269 PMCID： PMC526332 DOI： 10.1503/cmaj.1040563

Source DB: PubMed Journal: CMAJ ISSN： 0820-3946 Impact factor: 8.262

8 in total

1. Invasive pulmonary aspergillosis associated with infliximab therapy.

Authors: A Warris; A Bjørneklett; P Gaustad
Journal: N Engl J Med Date: 2001-04-05 Impact factor: 91.245

2. Does administration of infliximab increase susceptibility to listeriosis?

Authors: J Morelli; F A Wilson
Journal: Am J Gastroenterol Date: 2000-03 Impact factor: 10.864

3. Infliximab for the treatment of fistulas in patients with Crohn's disease.

Authors: D H Present; P Rutgeerts; S Targan; S B Hanauer; L Mayer; R A van Hogezand; D K Podolsky; B E Sands; T Braakman; K L DeWoody; T F Schaible; S J van Deventer
Journal: N Engl J Med Date: 1999-05-06 Impact factor: 91.245

Review 4. Nocardiosis.

Authors: P I Lerner
Journal: Clin Infect Dis Date: 1996-06 Impact factor: 9.079

5. Clinical experience with infliximab therapy in 100 patients with Crohn's disease.

Authors: R J Farrell; S A Shah; P J Lodhavia; M Alsahli; K R Falchuk; P Michetti; M A Peppercorn
Journal: Am J Gastroenterol Date: 2000-12 Impact factor: 10.864

6. Rapid identification of mycobacteria to the species level by polymerase chain reaction and restriction enzyme analysis.

Authors: A Telenti; F Marchesi; M Balz; F Bally; E C Böttger; T Bodmer
Journal: J Clin Microbiol Date: 1993-02 Impact factor: 5.948

7. A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis.

Authors: K V Narayanan Menon; Linda Stadheim; Patrick S Kamath; Russell H Wiesner; Gregory J Gores; Craig J Peine; Vijay Shah
Journal: Am J Gastroenterol Date: 2004-02 Impact factor: 10.864

8. Infliximab maintenance therapy for fistulizing Crohn's disease.

Authors: Bruce E Sands; Frank H Anderson; Charles N Bernstein; William Y Chey; Brian G Feagan; Richard N Fedorak; Michael A Kamm; Joshua R Korzenik; Bret A Lashner; Jane E Onken; Daniel Rachmilewitz; Paul Rutgeerts; Gary Wild; Douglas C Wolf; Paul A Marsters; Suzanne B Travers; Marion A Blank; Sander J van Deventer
Journal: N Engl J Med Date: 2004-02-26 Impact factor: 91.245

8 in total

5 in total

Review 1. Nocardia infections among immunomodulated inflammatory bowel disease patients: A review.

Authors: Cândida Abreu; Nuno Rocha-Pereira; António Sarmento; Fernando Magro
Journal: World J Gastroenterol Date: 2015-06-07 Impact factor: 5.742

2. Pulmonary nocardiosis in an adolescent patient with Crohn's disease treated with infliximab: a serious complication of TNF-alpha blockers.

Authors: Rishi Verma; Ritu Walia; Stephen B Sondike; Raheel Khan
Journal: W V Med J Date: 2015 May-Jun